Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Deferred Revenue (2016 - 2025)

Tg Therapeutics has reported Current Deferred Revenue over the past 10 years, most recently at $21.2 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $21.2 million for Q4 2025, up 86.03% from a year ago — trailing twelve months through Dec 2025 was $21.2 million (up 86.03% YoY), and the annual figure for FY2025 was $21.2 million, up 86.03%.
  • Current Deferred Revenue for Q4 2025 was $21.2 million at Tg Therapeutics, down from $26.4 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for TGTX hit a ceiling of $26.4 million in Q3 2025 and a floor of $152000.0 in Q4 2023.
  • Median Current Deferred Revenue over the past 5 years was $700000.0 (2021), compared with a mean of $6.4 million.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 69.6% in 2023 and later surged 7409.21% in 2024.
  • Tg Therapeutics' Current Deferred Revenue stood at $600000.0 in 2021, then decreased by 16.67% to $500000.0 in 2022, then tumbled by 69.6% to $152000.0 in 2023, then surged by 7409.21% to $11.4 million in 2024, then soared by 86.03% to $21.2 million in 2025.
  • The last three reported values for Current Deferred Revenue were $21.2 million (Q4 2025), $26.4 million (Q3 2025), and $23.9 million (Q2 2025) per Business Quant data.